{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:17:38Z","timestamp":1787797058777,"version":"build-2784847793"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":72,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are promising therapeutic alternatives for renal anemia because their hematopoietic effects are less influenced by inflammation. However, HIF-PHIs did not improve anemia in some cases, even at increasing doses. Since non-hemodialysis patients and various HIF-PHIs have not yet been examined, this study aimed to explore the factors associated with HIF-PHI resistance index (HRI) in all patients with chronic kidney disease (CKD) who received HIF-PHIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center, retrospective observational study included patients with dialysis-dependent or non-dialysis-dependent CKD who received HIF-PHIs. Spearman\u2019s rank correlation coefficients were calculated between the HRI and each factor. Factors associated with a high HRI were evaluated using univariate logistic regression analysis, followed by multivariate logistic regression analysis using statistically significant factors as covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The controlling nutritional status (CONUT) score was strongly correlated with HRI (score\u2009\u2265\u20095 [moderate to severe malnutrition] was associated with a high HRI). Further analysis of daprodustat (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200938) showed that this association remained significant after adjusting for potential confounders (OR\u2009=\u20092.2; 95% CI, 1.09\u20134.44;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.028).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Malnutrition, which is closely associated with anemia, may contribute to the reduced responsiveness to HIF-PHIs. A high HRI may be undesirable for any patient because of safety concerns and economic burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-026-05074-x","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:23:50Z","timestamp":1781609030000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of nutritional indices with hyporesponsiveness to hypoxia-inducible factor-prolyl hydroxylase inhibitors in patients with chronic kidney disease: a single-center retrospective observational study"],"prefix":"10.1186","volume":"27","author":[{"given":"Takuya","family":"Minamishima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Mizoguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Nishibori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Ikesue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"5074_CR1","doi-asserted-by":"publisher","first-page":"e0236132","DOI":"10.1371\/journal.pone.0236132","volume":"15","author":"T Sofue","year":"2020","unstructured":"Sofue T, Nakagawa N, Kanda E, Nagasu H, Matsushita K, Nangaku M, et al. Prevalence of anemia in patients with chronic kidney disease in Japan: a nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PLoS ONE. 2020;15:e0236132. https:\/\/doi.org\/10.1371\/journal.pone.0236132.","journal-title":"PLoS ONE"},{"key":"5074_CR2","doi-asserted-by":"publisher","first-page":"7322","DOI":"10.3390\/ijms25137322","volume":"25","author":"T Kuragano","year":"2024","unstructured":"Kuragano T. Treatment of anemia associated with chronic kidney disease: plea for considering physiological erythropoiesis. Int J Mol Sci. 2024;25:7322. https:\/\/doi.org\/10.3390\/ijms25137322.","journal-title":"Int J Mol Sci"},{"key":"5074_CR3","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1007\/s11739-021-02738-4","volume":"16","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Chen X-X, Zhang Y-F, Lou J-Z, Yuan H-B. Roxadustat for dialysis patients with erythropoietin hypo-responsiveness: a single-center, prospective investigation. Intern Emerg Med. 2021;16:2193\u20139. https:\/\/doi.org\/10.1007\/s11739-021-02738-4.","journal-title":"Intern Emerg Med"},{"key":"5074_CR4","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.2215\/CJN.05590611","volume":"6","author":"MZ Molnar","year":"2011","unstructured":"Molnar MZ, Tabak AG, Alam A, Czira ME, Rudas A, Ujszaszi A, et al. Serum erythropoietin level and mortality in kidney transplant recipients. Clin J Am Soc Nephrol. 2011;6:2879\u201386. https:\/\/doi.org\/10.2215\/CJN.05590611.","journal-title":"Clin J Am Soc Nephrol"},{"key":"5074_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40262-021-01095-x","volume":"61","author":"D Czock","year":"2022","unstructured":"Czock D, Keller F. Clinical pharmacokinetics and pharmacodynamics of roxadustat. Clin Pharmacokinet. 2022;61:347\u201362. https:\/\/doi.org\/10.1007\/s40262-021-01095-x.","journal-title":"Clin Pharmacokinet"},{"key":"5074_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s41100-020-00311-x","volume":"6","author":"S Kuriyama","year":"2020","unstructured":"Kuriyama S, Maruyama Y, Honda H. A new insight into the treatment of renal anemia with HIF stabilizer. Ren Replace Ther. 2020;6:63. https:\/\/doi.org\/10.1186\/s41100-020-00311-x.","journal-title":"Ren Replace Ther"},{"key":"5074_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000454818","volume":"45","author":"T Akizawa","year":"2017","unstructured":"Akizawa T, Tsubakihara Y, Nangaku M, Endo Y, Nakajima H, Kohno T, et al. Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. Am J Nephrol. 2017;45:127\u201335. https:\/\/doi.org\/10.1159\/000454818.","journal-title":"Am J Nephrol"},{"key":"5074_CR8","doi-asserted-by":"publisher","unstructured":"Haase VH. Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. Kidney Int Suppl (2011). 2021;11:8\u201325. https:\/\/doi.org\/10.1016\/j.kisu.2020.12.002.","DOI":"10.1016\/j.kisu.2020.12.002"},{"key":"5074_CR9","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.dmpk.2015.08.004","volume":"30","author":"K Hara","year":"2015","unstructured":"Hara K, Takahashi N, Wakamatsu A, Caltabiano S. Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects. Drug Metab Pharmacokinet. 2015;30:410\u20138. https:\/\/doi.org\/10.1016\/j.dmpk.2015.08.004.","journal-title":"Drug Metab Pharmacokinet"},{"key":"5074_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000527835","volume":"9","author":"J Li","year":"2023","unstructured":"Li J, Haase VH, Hao C-M. Updates on hypoxia-inducible factor prolyl hydroxylase inhibitors in the treatment of renal anemia. Kidney Dis (Basel). 2023;9:1\u201311. https:\/\/doi.org\/10.1159\/000527835.","journal-title":"Kidney Dis (Basel)"},{"key":"5074_CR11","doi-asserted-by":"publisher","first-page":"sfae051","DOI":"10.1093\/ckj\/sfae051","volume":"17","author":"T Nakanishi","year":"2024","unstructured":"Nakanishi T, Kuragano T. Growing concerns about using hypoxia-inducible factor prolyl hydroxylase inhibitors for the treatment of renal anemia. Clin Kidney J. 2024;17:sfae051. https:\/\/doi.org\/10.1093\/ckj\/sfae051.","journal-title":"Clin Kidney J"},{"key":"5074_CR12","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/jcph.2300","volume":"63","author":"Y Kouki","year":"2023","unstructured":"Kouki Y, Okada N, Saga K, Ozaki M, Saisyo A, Kitahara T. Disproportionality analysis on hypothyroidism with roxadustat using the Japanese Adverse Drug Event Database. J Clin Pharmacol. 2023;63:1141\u20136. https:\/\/doi.org\/10.1002\/jcph.2300.","journal-title":"J Clin Pharmacol"},{"key":"5074_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s41100-025-00646-3","author":"N Hanafusa","year":"2025","unstructured":"Hanafusa N, Abe M, Joki N, Hoshino J, Taniguchi M, Kikuchi K, et al. Ren Replace Ther. 2025;11:54. https:\/\/doi.org\/10.1186\/s41100-025-00646-3. Annual dialysis data report 2022, Japanese Society for Dialysis Therapy (JSDT) Renal Data Registry."},{"key":"5074_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/ndtplus\/sfp097","volume":"2","author":"X Bonafont","year":"2009","unstructured":"Bonafont X, Bock A, Carter D, Brunkhorst R, Carrera F, Iskedjian M, et al. A meta-analysis of the relative doses of erythropoiesis-stimulating agents in patients undergoing dialysis. NDT Plus. 2009;2:347\u201353. https:\/\/doi.org\/10.1093\/ndtplus\/sfp097.","journal-title":"NDT Plus"},{"key":"5074_CR15","first-page":"315","volume":"18","author":"A Vega","year":"2014","unstructured":"Vega A, Abad S, Verdalles U, Aragoncillo I, Velazquez K, Quiroga B, et al. Dose equivalence between continuous erythropoietin receptor activator (CERA), darbepoetin and epoetin in patients with advanced chronic kidney disease. Hippokratia. 2014;18:315\u20138.","journal-title":"Hippokratia"},{"key":"5074_CR16","doi-asserted-by":"publisher","first-page":"1349876","DOI":"10.3389\/fnut.2024.1349876","volume":"11","author":"B Yang","year":"2024","unstructured":"Yang B, Yang Y, Liu B, Yang M. Role of composite objective nutritional indexes in patients with chronic kidney disease. Front Nutr. 2024;11:1349876. https:\/\/doi.org\/10.3389\/fnut.2024.1349876.","journal-title":"Front Nutr"},{"key":"5074_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/1744-9987.14057","volume":"28","author":"G \u0218tefan","year":"2024","unstructured":"\u0218tefan G, Zugravu A, Stancu S. Glasgow prognostic score as an outcome predictor for patients initiating hemodialysis. Ther Apher Dial. 2024;28:34\u201341. https:\/\/doi.org\/10.1111\/1744-9987.14057.","journal-title":"Ther Apher Dial"},{"key":"5074_CR18","doi-asserted-by":"publisher","first-page":"1412709","DOI":"10.1155\/2024\/1412709","volume":"2024","author":"C Yang","year":"2024","unstructured":"Yang C, Yu Z, Peng B, Mao C, Li J, Cao Y. ALBI grade is associated with clinical outcomes of critically ill patients with AKI: a cohort study with cox regression and propensity score matching. Mediators Inflamm. 2024;2024:1412709. https:\/\/doi.org\/10.1155\/2024\/1412709.","journal-title":"Mediators Inflamm"},{"key":"5074_CR19","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10157-023-02432-z","volume":"28","author":"M Nangaku","year":"2024","unstructured":"Nangaku M, Ueta K, Nishimura K, Sasaki K, Hashimoto T. Factors affecting responsiveness of vadadustat in patients with anemia associated with chronic kidney disease: a post-hoc subgroup analysis of Japanese phase 3 randomized studies. Clin Exp Nephrol. 2024;28:391\u2013403. https:\/\/doi.org\/10.1007\/s10157-023-02432-z.","journal-title":"Clin Exp Nephrol"},{"key":"5074_CR20","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3390\/nu16040520","volume":"16","author":"A Takahashi","year":"2024","unstructured":"Takahashi A. Zinc supplementation enhances the hematopoietic activity of erythropoiesis-stimulating agents but not hypoxia-inducible factor-prolyl hydroxylase inhibitors. Nutrients. 2024;16:520. https:\/\/doi.org\/10.3390\/nu16040520.","journal-title":"Nutrients"},{"key":"5074_CR21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10157-024-02497-4","volume":"28","author":"Japanese Society of Nephrology","year":"2024","unstructured":"Japanese Society of Nephrology. Essential points from evidence-based clinical practice guideline for chronic kidney disease 2023. Clin Exp Nephrol. 2024;28:473\u201395. https:\/\/doi.org\/10.1007\/s10157-024-02497-4.","journal-title":"Clin Exp Nephrol"},{"key":"5074_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/nep.13835","volume":"26","author":"DYH Yap","year":"2021","unstructured":"Yap DYH, McMahon LP, Hao C-M, Hu N, Okada H, Suzuki Y, et al. Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors. Nephrol (Carlton). 2021;26:105\u201318. https:\/\/doi.org\/10.1111\/nep.13835.","journal-title":"Nephrol (Carlton)"},{"key":"5074_CR23","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/aje\/kwk052","volume":"165","author":"E Vittinghoff","year":"2007","unstructured":"Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007;165:710\u20138. https:\/\/doi.org\/10.1093\/aje\/kwk052.","journal-title":"Am J Epidemiol"},{"key":"5074_CR24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software EZR for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transpl"},{"key":"5074_CR25","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1093\/ndt\/gfq802","volume":"26","author":"V Panichi","year":"2011","unstructured":"Panichi V, Rosati A, Bigazzi R, Paoletti S, Mantuano E, Beati S, et al. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transpl. 2011;26:2641\u20138. https:\/\/doi.org\/10.1093\/ndt\/gfq802.","journal-title":"Nephrol Dial Transpl"},{"key":"5074_CR26","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s10157-022-02227-8","volume":"26","author":"S Tanaka","year":"2022","unstructured":"Tanaka S, Kitamura H, Tsuruya K, Kitazono T, Nakano T, FKR Study Collaboration Group. Prevalence, treatment status, and predictors of anemia and erythropoietin hyporesponsiveness in Japanese patients with non-dialysis-dependent chronic kidney disease: a cross-sectional study. Clin Exp Nephrol. 2022;26:867\u201379. https:\/\/doi.org\/10.1007\/s10157-022-02227-8.","journal-title":"Clin Exp Nephrol"},{"key":"5074_CR27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000521162","volume":"8","author":"HHL Wu","year":"2022","unstructured":"Wu HHL, Chinnadurai R. Erythropoietin-stimulating agent hyporesponsiveness in patients living with chronic kidney disease. Kidney Dis (Basel). 2022;8:103\u201314. https:\/\/doi.org\/10.1159\/000521162.","journal-title":"Kidney Dis (Basel)"},{"key":"5074_CR28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s41100-017-0114-y","volume":"3","author":"H Yamamoto","year":"2017","unstructured":"Yamamoto H, Nishi S, Tomo T, Masakane I, Saito K, Nangaku M, et al. 2015 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ren Replace Ther. 2017;3:36. https:\/\/doi.org\/10.1186\/s41100-017-0114-y.","journal-title":"Ren Replace Ther"},{"key":"5074_CR29","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1093\/ndt\/gfs368","volume":"28","author":"M Rattanasompattikul","year":"2013","unstructured":"Rattanasompattikul M, Molnar MZ, Zaritsky JJ, Hatamizadeh P, Jing J, Norris KC, et al. Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients. Nephrol Dial Transpl. 2013;28:1936\u201345. https:\/\/doi.org\/10.1093\/ndt\/gfs368.","journal-title":"Nephrol Dial Transpl"},{"key":"5074_CR30","doi-asserted-by":"publisher","first-page":"1044895","DOI":"10.3389\/fnut.2022.1044895","volume":"9","author":"HY Lee","year":"2022","unstructured":"Lee HY, Suh S-W, Hwang JH, Shin J. Responsiveness to an erythropoiesis-stimulating agent is correlated with body composition in patients undergoing chronic hemodialysis. Front Nutr. 2022;9:1044895. https:\/\/doi.org\/10.3389\/fnut.2022.1044895.","journal-title":"Front Nutr"},{"key":"5074_CR31","doi-asserted-by":"publisher","first-page":"e0245625","DOI":"10.1371\/journal.pone.0245625","volume":"16","author":"T Yajima","year":"2021","unstructured":"Yajima T, Yajima K, Takahashi H. Association of the erythropoiesis-stimulating agent resistance index and the geriatric nutritional risk index with cardiovascular mortality in maintenance hemodialysis patients. PLoS ONE. 2021;16:e0245625. https:\/\/doi.org\/10.1371\/journal.pone.0245625.","journal-title":"PLoS ONE"},{"key":"5074_CR32","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12882-019-1457-0","volume":"20","author":"A Gonz\u00e1lez-Ortiz","year":"2019","unstructured":"Gonz\u00e1lez-Ortiz A, Correa-Rotter R, V\u00e1zquez-Rangel A, Vega-Vega O, Espinosa-Cuevas \u00c1. Relationship between protein-energy wasting in adults with chronic hemodialysis and the response to treatment with erythropoietin. BMC Nephrol. 2019;20:316. https:\/\/doi.org\/10.1186\/s12882-019-1457-0.","journal-title":"BMC Nephrol"},{"key":"5074_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s41100-015-0002-2","volume":"1","author":"M Okazaki","year":"2015","unstructured":"Okazaki M, Komatsu M, Shiohira S, Kataoka H, Tsuchiya K, Kawaguchi H, et al. Associations between the erythropoiesis-stimulating agent resistance index and the geriatric nutritional risk index of maintenance hemodialysis patients and increased mortality. Ren Replace Ther. 2015;1:7. https:\/\/doi.org\/10.1186\/s41100-015-0002-2.","journal-title":"Ren Replace Ther"},{"key":"5074_CR34","doi-asserted-by":"publisher","first-page":"e0277921","DOI":"10.1371\/journal.pone.0277921","volume":"17","author":"I Narita","year":"2022","unstructured":"Narita I, Hayashi T, Maruyama S, Masaki T, Nangaku M, Nishino T, et al. Hyporesponsiveness to erythropoiesis-stimulating agent in non-dialysis-dependent CKD patients: The BRIGHTEN study. PLoS ONE. 2022;17:e0277921. https:\/\/doi.org\/10.1371\/journal.pone.0277921.","journal-title":"PLoS ONE"},{"key":"5074_CR35","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1159\/000519043","volume":"52","author":"T Akizawa","year":"2021","unstructured":"Akizawa T, Tanaka-Amino K, Otsuka T, Yamaguchi Y. Factors affecting doses of roxadustat versus darbepoetin alfa for anemia in nondialysis patients. Am J Nephrol. 2021;52:702\u201313. https:\/\/doi.org\/10.1159\/000519043.","journal-title":"Am J Nephrol"},{"key":"5074_CR36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4009\/jsdt.57.197","volume":"57","author":"K Nanmoku","year":"2024","unstructured":"Nanmoku K, Ishimitsu A, Abe M, Uchida D, Ando A, Okabe E. Efficacy and factors influencing dosage of roxadustat for erythropoietin-resistant anemia in hemodialysis patients. Nihon Toseki Igakkai Zasshi. 2024;57:197\u2013204. https:\/\/doi.org\/10.4009\/jsdt.57.197.","journal-title":"Nihon Toseki Igakkai Zasshi"},{"key":"5074_CR37","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/1744-9987.13609","volume":"25","author":"T Akizawa","year":"2021","unstructured":"Akizawa T, Yamaguchi Y, Majikawa Y, Reusch M. Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients. Ther Apher Dial. 2021;25:575\u201385. https:\/\/doi.org\/10.1111\/1744-9987.13609.","journal-title":"Ther Apher Dial"},{"key":"5074_CR38","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1186\/s12882-024-03877-4","volume":"25","author":"K Odajima","year":"2024","unstructured":"Odajima K, Arai S, Kido R, Anzai H, Gojo M, Taira S, et al. Erythrocyte indices and response to hypoxia-inducible factor prolyl hydroxylase inhibitors in chronic kidney disease patients with renal anemia: a retrospective study. BMC Nephrol. 2024;25:423. https:\/\/doi.org\/10.1186\/s12882-024-03877-4.","journal-title":"BMC Nephrol"},{"key":"5074_CR39","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/1471-2369-13-171","volume":"13","author":"SH Kang","year":"2012","unstructured":"Kang SH, Cho KH, Park JW, Yoon KW, Do JY. Impact of heavy proteinuria on clinical outcomes in patients on incident peritoneal dialysis. BMC Nephrol. 2012;13:171. https:\/\/doi.org\/10.1186\/1471-2369-13-171.","journal-title":"BMC Nephrol"},{"key":"5074_CR40","doi-asserted-by":"publisher","first-page":"390","DOI":"10.5551\/jat.63501","volume":"30","author":"S Tsuda","year":"2023","unstructured":"Tsuda S, Nakayama M, Tanaka S, Haruyama N, Yoshitomi R, Fukui A, et al. The association of controlling nutritional status score and prognostic nutritional index with cardiovascular diseases: the Fukuoka Kidney Disease Registry Study. J Atheroscler Thromb. 2023;30:390\u2013407. https:\/\/doi.org\/10.5551\/jat.63501.","journal-title":"J Atheroscler Thromb"},{"key":"5074_CR41","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.3390\/nu14112317","volume":"14","author":"K Takagi","year":"2022","unstructured":"Takagi K, Takahashi H, Miura T, Yamagiwa K, Kawase K, Muramatsu-Maekawa Y, et al. Prognostic value of the Controlling Nutritional Status (CONUT) score in patients at dialysis initiation. Nutrients. 2022;14:2317. https:\/\/doi.org\/10.3390\/nu14112317.","journal-title":"Nutrients"},{"key":"5074_CR42","doi-asserted-by":"publisher","first-page":"e079992","DOI":"10.1136\/bmjopen-2023-079992","volume":"14","author":"H Zhang","year":"2024","unstructured":"Zhang H, Liu N, Dang H. Association of the Controlling Nutritional Status (CONUT) score with all-cause and cause-specific mortality in patients with diabetic kidney disease: evidence from the NHANES 2009\u20132018. BMJ Open. 2024;14:e079992. https:\/\/doi.org\/10.1136\/bmjopen-2023-079992.","journal-title":"BMJ Open"},{"key":"5074_CR43","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1046\/j.1523-1755.2003.00803.x","volume":"63","author":"K Kalantar-Zadeh","year":"2003","unstructured":"Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63:793\u2013808. https:\/\/doi.org\/10.1046\/j.1523-1755.2003.00803.x.","journal-title":"Kidney Int"},{"key":"5074_CR44","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.3390\/nu15071554","volume":"15","author":"N Miano","year":"2023","unstructured":"Miano N, Di Marco M, Alaimo S, Coppolino G, L\u2019Episcopo G, Leggio S, et al. Controlling Nutritional Status (CONUT) score as a potential prognostic indicator of in-hospital mortality, sepsis and length of stay in an internal medicine department. Nutrients. 2023;15:1554. https:\/\/doi.org\/10.3390\/nu15071554.","journal-title":"Nutrients"},{"key":"5074_CR45","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/ndt\/gfae075","volume":"39","author":"S Stoumpos","year":"2024","unstructured":"Stoumpos S, Crowe K, Sarafidis P, Barratt J, Bolignano D, Del Vecchio L, et al. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association. Nephrol Dial Transpl. 2024;39:1710\u201330. https:\/\/doi.org\/10.1093\/ndt\/gfae075.","journal-title":"Nephrol Dial Transpl"},{"key":"5074_CR46","doi-asserted-by":"publisher","first-page":"16673","DOI":"10.1038\/s41598-022-20985-z","volume":"12","author":"Y Otaki","year":"2022","unstructured":"Otaki Y, Watanabe T, Shimizu M, Tachibana S, Sato J, Kobayashi Y, et al. Association of malnutrition with renal dysfunction and clinical outcome in patients with heart failure. Sci Rep. 2022;12:16673. https:\/\/doi.org\/10.1038\/s41598-022-20985-z.","journal-title":"Sci Rep"},{"key":"5074_CR47","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.ajkd.2020.05.006","volume":"76","author":"TA Ikizler","year":"2020","unstructured":"Ikizler TA, Burrowes JD, Byham-Gray LD, Campbell KL, Carrero J-J, Chan W, et al. KDOQI clinical practice guideline for nutrition in CKD: 2020 update. Am J Kidney Dis. 2020;76:S1\u2013107. https:\/\/doi.org\/10.1053\/j.ajkd.2020.05.006.","journal-title":"Am J Kidney Dis"},{"key":"5074_CR48","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.2215\/CJN.16011219","volume":"15","author":"T Akizawa","year":"2020","unstructured":"Akizawa T, Nangaku M, Yonekawa T, Okuda N, Kawamatsu S, Onoue T, et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial. Clin J Am Soc Nephrol. 2020;15:1155\u201365. https:\/\/doi.org\/10.2215\/CJN.16011219.","journal-title":"Clin J Am Soc Nephrol"},{"key":"5074_CR49","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.3390\/ijms24033037","volume":"24","author":"C Ogawa","year":"2023","unstructured":"Ogawa C, Tsuchiya K, Maeda K. Hypoxia-inducible factor prolyl hydroxylase inhibitors and iron metabolism. Int J Mol Sci. 2023;24:3037. https:\/\/doi.org\/10.3390\/ijms24033037.","journal-title":"Int J Mol Sci"},{"key":"5074_CR50","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1159\/000169658","volume":"29","author":"C-K Chiang","year":"2009","unstructured":"Chiang C-K, Yang S-Y, Peng Y-S, Hsu S-P, Pai M-F, Huang J-W, et al. Atorvastatin increases erythropoietin-stimulating agent hyporesponsiveness in maintenance hemodialysis patients: role of anti-inflammation effects. Am J Nephrol. 2009;29:392\u20137. https:\/\/doi.org\/10.1159\/000169658.","journal-title":"Am J Nephrol"},{"key":"5074_CR51","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s12325-024-03015-4","volume":"42","author":"C Atzinger","year":"2025","unstructured":"Atzinger C, Arens H-J, Neri L, Arkossy O, Garbelli M, Jiletcovici A, et al. Hyporesponsiveness to erythropoiesis-stimulating agents in dialysis-dependent patients with anaemia of chronic kidney disease: a retrospective observational study. Adv Ther. 2025;42:471\u201389. https:\/\/doi.org\/10.1007\/s12325-024-03015-4.","journal-title":"Adv Ther"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-05074-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05074-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05074-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:30:21Z","timestamp":1787794221000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-05074-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5074"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-05074-x","relation":{"references":[{"id-type":"doi","id":"10.1186\/s41100-025-00646-3","asserted-by":"subject"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki and Ethical Guidelines for Medical and Health Research Involving Human Subjects, and was approved by the Institutional Review Board of Nagoya University Hospital (approval No. 2023\u2009\u2212\u20090475). As this was a retrospective study based on medical records, neither written nor verbal consent was obtained from participants. Information about the study, including the option to opt out, was publicly disclosed in written form on the Nagoya University Hospital website, and participants or their legal representatives were allowed to decline participation.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"503"}}